A randomised, phase 2 UK multi-centre study to determine reactogenicity of booster vaccination against ancestral and novel variants of SARS-CoV-2

Study code
NBR137

Lead researcher
Professor Krishna Chatterjee

Study type
Participant re-contact

Institution or company
Wellcome-MRC Institute of Metabolic Science, Cambridge

Speciality area
Infection

Summary

With the emergence of SARS-CoV-2 variants which may reduce vaccine efficacy against COVID-19, and with waning of immunity over time, it is likely that seasonal booster vaccines may be necessary for high risk groups. This study is to determine the safety and immune responses seen when people receive a COVID-19 booster vaccination, depending on whether they have received either the Oxford/AZ or Pfizer vaccines as their original course of 2 vaccines (known as prime-boost).  

The NIHR Cambridge Clinical Research Facility is recruiting to this study and would like to invite 40 COVID BioResource panel members aged >70 years who have received both doses of prime boost vaccination (Oxford/AZ or Pfizer), with the second dose being at least 70 days ago, to participate in this trial.